An observational study in Glucose Homeostasis, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by McMaster University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies in Insulin Resistance with a site in Canada — 21 open to participants now, 27 under way, 4 of them phase 3. Insulin Resistance · Canada.
Among the 197 studies in Insulin Resistance with a site in Canada, this one is the 9th largest by planned enrollment of the 23 observational ones that give a count, is one of 9 that started in 2025, is one of 23 observational ones, reaches primary completion later than 22 of the 26 other live ones, and was the 187th registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →21 of the 197 studies in Insulin Resistance with a site in Canada are open now. Recruiting first, the newest first:
May Faraj, PDt, PhD · Sites in Canada
Ages 40–70 · Healthy volunteers
University of Toronto · Sites in Canada
Ages 14–80
University of New Brunswick · Sites in Canada
Ages 19+ · Women only · Healthy volunteers
Université de Sherbrooke · Sites in Canada
Ages 40–75
Laval University · Sites in Canada
Ages 25–70 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 39 · Phase 3 25 · Phase 4 13
First in 1994; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 81 across 480 observational studies indexed under Insulin Resistance.
Median enrollment 30 across the 172 interventional studies, 30 across the 23 observational. Of the 142 that completed or were terminated, 17 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 197 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 4 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
11 of the studies in Insulin Resistance with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
| NCT04578652Phase 3University of AlbertaFiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance | 2027-02 |
| NCT07460856Laval UniversityEffects of Cranberry on Gut and Metabolic Health | 2026-12 |
| NCT05188222Jewish General HospitalPreoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery | 2026-12-01 |
| NCT06251635Centre for Addiction and Mental HealthEffects of Antipsychotics on Brain Insulin Action in Females | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 197 studies in Insulin Resistance with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Goals: The long-term use of hormonal birth control has been shown to effect glucose handling, or blood sugar regulation, and potentially lead to insulin resistance which increases a person's risk for metabolic diseases such as type 2 diabetes. The goal of this study is to investigate how the body handles glucose, in three groups of young, healthy females: NAT (naturally cycling, or not using hormonal birth control), OCP (taking a birth control pill), and IUD (using an intrauterine device). Objectives: We will investigate if the body's ability to handle glucose differs between these groups. We will also explore if these differences are linked to the levels of primary sex hormones in females, estrogen and progesterone, and if the synthetic versions produced by hormonal birth control have the same negative effect. We will use an oral glucose tolerance test to investigate these potential differences, having participants drink a 75 gram glucose beverage and taking blood samples every 15-30 minutes for a 2-hour timespan. These blood samples will be used to measure glucose and insulin levels in the blood to determine any changes that occur in the body in response to glucose.
Insulin resistance is a common metabolic condition, and is considered a primary risk factor for the development of type 2 diabetes (T2D). As the prevalence of T2D continues to rise, particularly among premenopausal females (18-45 years), it is imperative to conduct additional research in this area. Fluctuations in primary sex hormones in females have been shown to modulate risk for developing impaired glucose tolerance, however, research in this area as well as work investigating synthetic versions of these hormones for OCP and IUD users remains unclear. It is crucial to investigate how hormonal contraceptives can alter glucose tolerance in young, otherwise healthy females, and what downstream effects contraceptives could have later in life.
We will recruit 54 young healthy recreationally active females (n=18 per group) 18-45 years of age from the following groups: 1) individuals currently taking second generation OCPs containing levonorgestrel, 2) individuals with a levonorgestrel-releasing IUD, and 3) NAT individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NAT females:
OCP users:
IUD users:
Exclusion Criteria:
NAT females:
OCP users:
IUD users:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Naturally-cycling females
Diagnostic Test: Oral Glucose Tolerance test (75g 2-hour)
Combined oral contraceptive users
Diagnostic Test: Oral Glucose Tolerance test (75g 2-hour)
Hormonal intrauterine device users
Diagnostic Test: Oral Glucose Tolerance test (75g 2-hour)
Standard oral glucose tolerance test with blood draws every 15-30 minutes for a 2-hour span
Glucose tolerance
A 2-hour oral glucose tolerance test will be performed in fasted individuals
Time frame: 2 hours
Glucose and lipid metabolites
Peak concentration of whole blood glucose
Time frame: Timepoints: 0 minute, 15 minute, 30 minute, 45 minute, 60 minute, 90 minute, 120 minute
Glucose and lipid metabolites
Insulin
Time frame: Timepoints: 0 minute, 15 minute, 30 minute, 45 minute, 60 minute, 90 minute, 120 minute
Glucose and lipid metabolites
C-peptide
Time frame: Timepoints: 0 minute, 15 minute, 30 minute, 45 minute, 60 minute, 90 minute, 120 minute
Glucose and lipid metabolites
Concentration of total and high-density lipoprotein cholesterols
Time frame: Fasting (0 min timepoint)
Glucose and lipid metabolites
Concentration of non-esterified fatty acids (NEFAs)
Time frame: Fasting (0 min timepoint)
Hormone availability
Concentration of 17b estradiol (endogenous estrogen)
Time frame: Fasting (0 min timepoint)
Hormone availability
Concentration of endogenous progesterone
Time frame: Fasting (0 min timepoint)
Hormone availability
Concentration of ethinyl estradiol (exogenous estrogen)
Time frame: Fasting (0 min timepoint)
Hormone availability
Concentration of levonorgestrel (exogenous progesterone)
Time frame: Fasting (0 min timepoint)
Plan to share: No — To protect participant privacy, IPD will not be available to other researchers.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jul 2027, 21 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jul 2026 → Jul 2027 and completion Oct 2026 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.